Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q2 2024 Earnings Conference Call July 29, 2024 4:30 PM ET
Company Participants
Matt Steinberg - Finn Partners
Scott Davis - Chief Executive Officer
Jerome Wong - Chief Financial Officer
Conference Call Participants
Ben Haynor - Lake Street Capital Markets
Li Chen - H.C. Wainwright
Operator
Greetings, and welcome to the Ekso Bionics' Q2 2024 Financial Results Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Matt Steinberg with Finn Partners. Thank you, Matt. You may begin.
Matt Steinberg
Thank you, operator, and thank you all for participating in today's call. Joining me from Ekso Bionics are Scott Davis, Chief Executive Officer; and Jerome Wong, Chief Financial Officer. Earlier today, Ekso Bionics released financial results for the quarter ended June 30, 2024. A copy of the press release is available on the company's website.
Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements, including statements regarding our business strategy, future financial or operating expectations or our expectations of the regulatory landscape governing our products and operations are based upon management's current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with EXO's businesses, please see its filings with the Securities and Exchange Commission. Esko's businesses, please see its filings with the Securities and Exchange Commission. Esko's disclaims any obligation, except as required by law, to update or revise any financial or operational projections, its regulatory outlook or other forward-looking statements, whether because of new information, future events or otherwise. Any forward-looking statements made on this call speak only as of the date of this call.
I will now turn the call over to Ekso Bionic's Chief Executive Officer, Scott Davis.